ImmunoPrecise Antibodies’ (IPA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of ImmunoPrecise Antibodies (NASDAQ:IPA) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

ImmunoPrecise Antibodies Stock Down 5.0 %

IPA stock opened at $0.38 on Friday. The firm has a market cap of $11.96 million, a PE ratio of -0.49 and a beta of 0.09. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01. The firm’s fifty day moving average is $0.46 and its 200 day moving average is $0.49. ImmunoPrecise Antibodies has a one year low of $0.27 and a one year high of $1.64.

Institutional Trading of ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC boosted its position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,558,892 shares of the company’s stock after buying an additional 263,451 shares during the quarter. Ingalls & Snyder LLC owned approximately 5.41% of ImmunoPrecise Antibodies worth $996,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.70% of the company’s stock.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.